Our Top Ten Items from a Year Most Want to Forget

From the bear market, to the growing management credibility gap, to GPO whistleblowers, 2002 was a year most of us are glad to have behind us. But within the gloom, some glimmers of hope: most important among them is a sense of directionality at athe FDA following the appointment of a new commissioner.

1) The Ugly Market. Without question, issue number one for 2002. Stock funds fled health care, the pervasive bleakness dulling, not highlighting, the few bright spots. Both Big Pharma and biotech badly underperformed the Dow, dropping 21% and 34%, respectively. Medical devices did relatively well—a mere 15% decline. But even there, consolidation skews the numbers—a few winners, like Stryker Corp. and Boston Scientific Corp. , dramatically helped the index. In no segment could a small public company without great news buy an investor. IPOs were virtually nonexistent. The depression in the public market translated directly to a depression on the private side: valuations of follow-on financings, when they could be found, plummeted. Layoffs—both in anticipation of a financing squeeze and because of them—were common as even well-funded businesses tightened their belts in anticipation of a long financial drought: discovery scientists were hardest hit.

2) The Management Credibility Gap. One key reason for the market problems: distrust of management. Corporate malfeasance turned personal in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

More from In Vivo

Deals In Depth: June 2025

 
• By 

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.